Short peptide derivatives based on lysosomal membrane protein 2A and their applications

By synthesizing short peptide derivatives L2AK104, L2AK289, L2AK132 and L2ASIM1 based on lysosomal membrane protein 2A, the problem of the lack of KSHV targeted therapy in the prior art has been solved, and effective inhibition of KSHV virus infection and tumors has been achieved, providing a new treatment approach.

CN119684468BActive Publication Date: 2026-11-10FUDAN UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411650883.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-11-19
Publication Date
2026-11-10
Estimated Expiration
2044-11-19

AI Technical Summary

Technical Problem

There is a lack of effective targeted therapy strategies in the current technology to address tumors and latent viral infections caused by Kaposi's sarcoma virus (KSHV), especially for diseases such as KSHV-associated malignant lymphoma and Kaposi's sarcoma.

Method used

We designed and synthesized short peptide derivatives based on lysosomal membrane protein 2A, namely L2AK104, L2AK289, L2AK132 and L2ASIM1, which competitively inhibited SUMO modification of LAMP2A and interfered with the interaction between TRIM32 and LAMP2A, thereby inhibiting the increase in KSHV viral copy number and tumor growth.

Benefits of technology

These short peptide derivatives are stable in vivo, exhibit high specificity and low cytotoxicity, and can significantly inhibit KSHV virus infection and tumor growth, providing a potential therapeutic strategy for KSHV-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119684468B_ABST
    Figure CN119684468B_ABST
Patent Text Reader

Abstract

This invention discloses a short peptide derivative based on lysosomal membrane protein 2A and its uses. The short peptide derivatives of this invention are L2AK104, L2AK289, L2AK132, and L2ASIM1, whose amino acid sequences are shown in SEQ ID No. 6-9. The short peptide derivatives consist of a transmembrane peptide and a short peptide. The short peptide is a short peptide based on SUMO modification of the lysosomal membrane protein 2A polypeptide at the K104, K289, K132, and SIM1 sites, whose amino acid sequences are shown in SEQ ID No. 1-4. The transmembrane peptide is attached to the N-terminus of the short peptide, and the amino acid sequence of the transmembrane peptide is shown in SEQ ID No. 5. The four short peptide derivatives in this invention do not affect cell viability and have no cytotoxicity. Furthermore, using the tumor virus KSHV as a research model, this invention has repeatedly confirmed in vivo experiments that these four short peptide derivatives have a certain inhibitory effect on KSHV and other viral infections and tumor cell proliferation. They can be used to prepare related drugs for the treatment of KSHV and tumor diseases, and have important application value for the prevention and targeted treatment of KSHV and other virus-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, specifically to a short peptide derivative based on lysosomal membrane protein 2A and its uses. Background Technology

[0002] Statistics show that viral infection is closely related to the development and progression of approximately 20% of tumors, making it one of the main contributing factors. Oncogenic viruses can cause tumors in humans or animals, and even induce malignant transformation of normal cells in vitro. To date, several human tumor viruses have been identified, including Kaposi's sarcoma-associated herpesvirus (KSHV), Epstein-Barr virus (EBV), and human papillomavirus (HPV). Viruses can promote tumorigenesis through various mechanisms, including gene integration, chronic inflammation, immune evasion, and regulation of host cell signaling pathways. Among them, Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8 (HHV-8), is an enveloped virus containing double-stranded DNA. It was first identified by Chang and Moore in 1994 from the tissue of Kaposi's sarcoma patients infected with human immunodeficiency virus. Like Epstein-Barr virus (EBV), it belongs to the human gamma herpesvirus subfamily. It is a tumor virus that can infect various cell types, including B cells, endothelial cells, and epithelial cells, and is closely associated with a variety of human malignancies, including primary exudative lymphoma, Kaposi's sarcoma, and multiple central lymphoma.

[0003] Similar to other herpesviruses, KSHV has two life cycles: a latent period and a lysis replication period. In tumor tissues and cells, it primarily exists as a latent infection. Global KSHV infection rates are estimated at 2% to 10%, but vary significantly geographically, with generally lower rates in South America and higher rates among Native Americans. Extensive clinical data indicates that deaths in AIDS patients are not primarily due to HIV infection itself, but rather to complications including KSHV-induced systemic malignant lymphoma. It is estimated that approximately 14% of AIDS deaths are caused by cancers associated with KSHV-related Kaposi's sarcoma, and about 60,000 new cases of primary exudative lymphoma are diagnosed worldwide each year, yet there are currently no effective targeted therapies. Therefore, in-depth research into the mechanisms of KSHV infection and tumorigenesis is urgently needed to provide effective potential targeted intervention strategies for treating KSHV-related diseases. Summary of the Invention

[0004] The purpose of this invention is to address the aforementioned problems in the prior art and provide a short peptide derivative based on lysosomal membrane protein 2A and its uses. The short peptide derivative based on lysosomal membrane protein 2A in this invention is a stable polypeptide compound that can penetrate cell membranes to enter tumor cells. It exhibits high specificity, efficacy, and low cytotoxicity against latent infections caused by viruses such as KSHV, and demonstrates significant inhibitory efficiency against KSHV and other viral infections, as well as tumor growth, proliferation, and angiogenesis.

[0005] To solve the above-mentioned technical problems, the present invention adopts the following technical solution: based on short peptide derivatives of lysosomal membrane protein 2A, wherein the short peptide derivatives are L2AK104, L2AK289, L2AK132 and L2ASIM1; the amino acid sequences of L2AK104, L2AK289, L2AK132 and L2ASIM1 are shown in SEQ ID No. 6-9 in sequence.

[0006] Preferably, the short peptide derivative is composed of a membrane-penetrating peptide and a short peptide, wherein the short peptide is a short peptide based on the SUMO modification of lysosomal membrane protein 2A polypeptide at sites K104, K289, K132, and SIM1, and the short peptides at sites K104, K289, K132, and SIM1 correspond sequentially to the short peptide derivatives L2AK104, L2AK289, L2AK132, and L2ASIM1, respectively. The amino acid sequences of the short peptides at sites K104, K289, K132, and SIM1 are shown in SEQ ID No. 1-4, respectively. The membrane-penetrating peptide is attached to the N-terminus of the short peptide, and the amino acid sequence of the membrane-penetrating peptide is shown in SEQ ID No. 5.

[0007] The chemical structures of the short peptides at sites K104, K289, K132, and SIM1 are as follows:

[0008] Short peptide at K104 site

[0009]

[0010] Short peptide at K289 site

[0011]

[0012] Short peptide at K132 site

[0013]

[0014] Short peptide at SIM1 site

[0015]

[0016] Preferably, the short peptide derivative is prepared by solid-phase synthesis.

[0017] The present invention provides a pharmaceutical formulation comprising one or two of the above-mentioned short peptide derivatives.

[0018] The present invention also provides the use of the above-mentioned short peptide derivative in the preparation of antiviral infection drugs, wherein the virus is Kaposi's sarcoma virus (KSHV), and the short peptide derivative can inhibit the increase of viral copy number of KSHV.

[0019] The present invention also provides the use of the above-mentioned short peptide derivative in the preparation of a drug for treating tumors, wherein the tumor is a tumor caused by Kaposi's sarcoma virus (KSHV), and the short peptide derivative can inhibit the proliferation of KSHV virus-positive tumor cells, inhibit tumor growth and angiogenesis.

[0020] Infections with viruses such as KSHV can induce TRIM32-regulated SUMO modification of LAMP2A, leading to a large accumulation of LAMP2A, which is one of the important factors in maintaining latent infection of KSHV and other viruses and inducing related diseases. LAMP2A is a key protein in heat shock protein-mediated autophagy, and TRIM32 regulates SUMO modification of LAMP2A under viral infection; the main function of this interaction is to promote high expression of LAMP2A. In this invention, a series of experiments were conducted to identify the sites of SUMO modification of LAMP2A, and peptides related to the K104, K289, K132, and SIM1 sites were screened. These peptides can competitively inhibit SUMO modification of LAMP2A, suppressing LAMP2A protein expression, thereby exerting anti-KSHV and other viral infections and anti-tumor effects.

[0021] This invention designs several LAMP2A-derived peptide compounds, L2AK104, L2AK289, L2AK132, and L2ASIM1. The peptide sequences and lengths are determined using the LAMP2A gene sequence and specific SUMO modification sites. The effects of these peptide compounds on cell viability and toxicity are detected using a CCK-8 assay. The effects of different peptide compounds on the proliferation of KSHV and other virus-related tumor cells are compared through clonal generation. Furthermore, using a mouse tumor-bearing model, the effects of different peptide compounds on the growth and angiogenesis of KSHV and other virus-related tumors are verified, providing a new strategy for the treatment of KSHV and other virus-related diseases.

[0022] The beneficial effects of this invention are as follows: This invention provides four short peptide derivatives based on lysosomal membrane protein 2A, namely L2AK104, L2AK289, L2AK132, and L2ASIM1. These four short peptide derivatives do not affect cell viability and are non-cytotoxic. Furthermore, using the tumor virus KSHV as a research model, this invention has repeatedly confirmed in vivo experiments that these four short peptide derivatives have a certain inhibitory effect on KSHV and other viral infections and tumor cell proliferation, laying the foundation for the treatment of KSHV and other viral infections and tumor diseases. Attached Figure Description

[0023] Figure 1 Figure 1 shows the results of Example 1; where A) the interaction between TRIM32 and CMA autophagy-related proteins before and after KSHV virus infection; B) the co-localization of TRIM32 and CMA autophagy-related proteins before and after KSHV virus infection; C) knocking down TRIM32 or LAMP2A in KSHV-infected cells can restore the expression level of CMA substrate MEF2D; D) the structural domains of TRIM32 and LAMP2A interaction before and after simulated DNA virus infection; E) TRIM32 overexpression can enhance DNA virus infection-induced LAMP2A protein SUMO2 / 3 modification; F) loss of the RING domain can inhibit TRIM32-mediated LAMP2A SUMO2 / 3 modification.

[0024] Figure 2 The K104,289 and K132,SIM1 sites are conducive to DNA viral infection inducing LAMP2A to undergo SUMO2 and SUMO3 modifications, respectively.

[0025] Figure 3 The diagram shows the results of TRIM32 regulating SUMO modification of LAMP2A to inhibit KSHV viral copy number and expression of key viral proteins in Example 3; where A) TRIM32 activates RTA degradation through modification of LAMP2A at K104,289 and K132,SIM1 sites; B) TRIM32 inhibits the production of daughter virus particles through modification of LAMP2A at K104,289 and K132,SIM1 sites.

[0026] Figure 4 The figure shows the effect of TRIM32-mediated LAMP2A SUMO modification on subcutaneous tumor growth and angiogenesis in Example 3; where A) is a schematic diagram of the mouse tumor-bearing experiment design; B) is a comparison of tumor size and tumor weight between experimental groups; and C) is a comparison of representative tumors and surrounding angiogenesis in each experimental group.

[0027] Figure 5The purity of different short peptides synthesized from LAMP2A was determined by HPLC; where A) L2AK104; B) L2AK104R; C) L2AK289; D) L2AK289R; E) L2AK132; F) L2AK132R; G) L2ASIM1; H) L2AmSIM1.

[0028] Figure 6 The effects of different short peptides on cell (iSLK-Bac16) viability were detected using CCK-8 assay.

[0029] Figure 7 The effects of different short peptide compounds of LAMP2A on the growth and angiogenesis of subcutaneous tumors infected with KSHV virus are shown in the following diagrams: (A) Schematic diagram of the mouse tumor-bearing experiment design; (B) Comparison of tumor size and tumor weight among the experimental groups; (C) Comparison of representative tumors and surrounding angiogenesis in each experimental group; (D) Schematic diagram of mouse body weight among the experimental groups.

[0030] KSHV-negative endothelial cells (including MM and iSLK) and their corresponding KSHV-positive cells (including KMM and iSLK-Bac16) have been published in the following literature:

[0031] [1]BRULOIS KF, CHANG H, LEE A SY, et al. Construction and Manipulation of a New Kaposi's Sarcoma-Associated Herpesvirus Bacterial Artificial Chromosome Clone[J].2012,86(18):9708-20.

[0032] [2]MYOUNG J,GANEM D.Generation of a doxycycline-inducible KSHVproducer cell line of endothelial origin:Maintenance of tight latency with efficient reactivation upon induction[J].Journal of Virological Methods, 2011,174(1):12-21.

[0033] [3]JONES T,YE F,BEDOLLA R,et al.Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV[J].J ClinInvest,2012,122(3):1076-81. Detailed Implementation

[0034] The present invention will be further described below with reference to the accompanying drawings and specific embodiments.

[0035] Example 1: Effects of viral infection on the expression, localization, and modification levels of the autophagy-related protein LAMP2A of TRIM32 and CMA.

[0036] 1. KSHV infection promotes the interaction and co-localization of TRIM32 and LAMP2A.

[0037] TRIM32 is highly expressed in KS tumor tissues and is involved in the regulation of heat shock protein-mediated autophagy (CMA). To examine the association between CMA and TRIM32 before and after KSHV infection, two types of KSHV-negative endothelial cells (including MM and iSLK) and their corresponding KSHV-positive cells (including KMM and iSLK-Bac16) were tested. [1-3] Immunoprecipitation and Western blot analysis were performed using a TRIM32-specific antibody, with the specific substrate MEF2D selected as the CMA activity marker for simultaneous detection. Results are as follows: Figure 1 As shown in Figure A, compared to uninfected KSHV cells, the interaction between TRIM32 and HSC70 and LAMP2A was significantly enhanced in KSHV-positive cells, while its interaction with HSP90 was significantly weakened. Furthermore, KSHV infection revealed significantly increased expression levels of LAMP2A and TRIM32, and significantly decreased expression levels of MEF2D, a CMA-specific substrate, while other protein levels remained largely unchanged. This suggests that KSHV infection promotes the interaction of TRIM32 with HSC70 and LAMP2A, but inhibits its interaction with HSP90, thereby promoting CMA activation.

[0038] Next, the co-localization of TRIM32 and its target proteins after KSHV infection was further detected by immunofluorescence. Figure 1(B) The results showed that, compared with KSHV-negative cells, HSC70, HSP90, and LAMP2A all entered the nucleus in KSHV-positive endothelial cells. LAMP2A, in particular, showed significant nuclear aggregation and co-localization with TRIM32. This indicates that HSC70, HSP90, and LAMP2A responded to KSHV infection by undergoing nuclear translocation and co-localized with TRIM32 to varying degrees, with the co-localization between TRIM32 and LAMP2A being the most pronounced.

[0039] In summary, during viral infection, TRIM32 mainly regulates the CMA pathway through its interaction with LAMP2A.

[0040] 2. TRIM32 knockdown affects LAMP2A protein expression.

[0041] To further verify the association between TRIM32 and LAMP2A, this embodiment used lentiviral packaging to construct stable cell lines with knockdown of TRIM32 and LAMP2A, respectively. Next, the expression levels of LAMP2A, TRIM32, and MEF2D were detected using Western blotting with the constructed stable TRIM32 / LAMP2A knockdown cell lines. Figure 1 As shown in Figure C, when TRIM32 expression levels decrease, LAMP2A expression levels also decrease, while MEF2D expression levels increase; conversely, when LAMP2A expression levels decrease, TRIM32 expression levels are not significantly affected, and MEF2D expression levels significantly increase. Given that downregulation of TRIM32 expression leads to decreased LAMP2A expression and upregulation of MEF2D expression, this suggests that TRIM32 positively regulates LAMP2A expression, acting as an upstream molecule to target and enhance CMA activity through LAMP2A.

[0042] 3. TRIM32 affects the modification level of LAMP2A.

[0043] To clarify which specific domain of TRIM32 is involved in the LAMP2A interaction, this embodiment constructed mutants of TRIM32 with different domain deletions tagged with EGFP. Wild-type TRIM32 with an EGFP tag and its truncated variants were transfected into HEK293T cells. A control group and a poly(dA:dT) treatment group simulating viral infection were included. The interaction between TRIM32 and its target proteins was then detected using co-immunoprecipitation and Western blotting methods. Figure 1As shown in Figure D, under unstimulated conditions, the interaction between LAMP2A and TRIM32 disappears or weakens when the RING or CC domains of TRIM32 are missing, while the interaction is significantly enhanced when the NHL domain of TRIM32 is missing. After poly(dA:dT) stimulation, TRIM32 exhibits multimerization when the CC domain is missing, and its interaction with the LAMP2A-modified state is significantly enhanced. This suggests that under normal physiological conditions, the interaction between LAMP2A and TRIM32 depends on the RING and CC domains of TRIM32; under poly(dA:dT) stimulation, TRIM32 interacts with the modified LAMP2A through its RING and CC domains.

[0044] Given the impact of SUMO modification on protein localization, and the significant co-localization of TRIM32 with LAMP2A under KSHV infection, it is hypothesized that TRIM32 may be involved in regulating SUMO modification of LAMP2A. To further verify this, HEK293T cells were co-transfected with FLAG-tagged LAMP2A, HA-tagged SUMO1, SUMO2 or SUMO3, and TRIM32-myc. Twenty-four hours after transfection, cells were stimulated with poly(dA:dT) for 24 hours. Detection was performed using denaturing immunoprecipitation and Western blotting experiments. Figure 1 As shown in Figure E, upon poly(dA:dT) stimulation, the levels of all three modifications of LAMP2A (including SUMO1, SUMO2, and SUMO3) increased. Furthermore, when TRIM32 was overexpressed, the SUMO1 modification level of LAMP2A was significantly reduced, while the levels of SUMO2 and SUMO3 modifications were significantly increased. This indicates that under poly(dA:dT) stimulation, TRIM32 can induce SUMO2 and SUMO3 modifications in LAMP2A protein, while inhibiting SUMO1 modification.

[0045] In this embodiment, LAMP2A and either SUMO2 or SUMO3 were simultaneously overexpressed in HEK293T cells. After transfection for 24 hours, the cells were treated with poly(dA:dT) for another 24 hours. The modification status of LAMP2A was detected by denaturing immunoprecipitation and Western blotting. A RING domain deletion mutant was used as a control. The results are as follows: Figure 1 As shown in Figure F, overexpression of TRIM32 significantly promotes SUMO2 or SUMO3 modification in LAMP2A. When the RING domain is missing, the SUMO2 modification level of LAMP2A is significantly reduced, while the SUMO3 modification level remains unchanged. These data indicate that TRIM32 primarily induces SUMO2 modification in LAMP2A through the RING domain, while the SUMO3 modification level is not dependent on the RING domain.

[0046] The experimental steps involved in this embodiment are as follows:

[0047] 1. Preparation for cell sample lysis:

[0048] 1) Collect an appropriate amount of cells, centrifuge at 2500 rpm for 3 min at room temperature, and discard the culture medium.

[0049] 2) Wash twice with pre-cooled PBS, centrifuge at 2500 rpm for 3 min at room temperature, and discard the PBS.

[0050] 3) Add an appropriate amount of RIPA protein lysis buffer containing protease inhibitors (1% NP-40, 2mM EDTA, 150mM NaCl, 50mM Tris (pH 7.6), 1mM PMSF, 1mM NEM, 1g / mL Aprotinin, 1g / mL leupeptin and 1g / mL pepstatin), and lyse on ice for 30 min.

[0051] 4) Shake once every 5 minutes to ensure complete decomposition.

[0052] 5) Centrifuge the fully lysed cells at 14,500 rpm for 5 min in a centrifuge at 4°C.

[0053] 6) Transfer the supernatant after centrifugation to a new EP tube, which is the whole cell lysis buffer. Measure the protein concentration according to the Coomassie Brilliant Blue G-250 method.

[0054] 7) Aliquot the protein sample according to the loading amount, add 6X protein loading solution, and boil in a 100°C metal bath for 5 minutes until the protein denatures.

[0055] 8) Protein samples can be frozen at -80℃ for later use or directly used for immunoblotting experiments.

[0056] 2. Procedure for Western blotting protein immunoblotting:

[0057] 1) SDS-PAGE electrophoresis: Add the above denatured protein samples to an appropriate concentration of SDS-PAGE gel for gel electrophoresis separation.

[0058] 2) Transfer: A 0.45 μm NC membrane was immersed in 1X NC membrane transfer equilibration buffer and transferred using GenScript eBlot. TM The L1 rapid wet transfer apparatus uses a standard procedure for film transfer, which takes approximately 10 minutes.

[0059] 3) Blocking: Place the NC membrane in 5% skim milk powder (prepared with PBS) and incubate at room temperature for 1 hour.

[0060] 4) Primary antibody incubation: Wash 3 times with TBST at room temperature for 5 minutes each time, add the primary antibody diluted in an appropriate ratio, and incubate overnight at 4°C.

[0061] 5) Secondary antibody incubation: Wash 3 times with TBST at room temperature, 5 min each time, using the corresponding species' fluorescent secondary antibody 800.

[0062] 6) Incubate at room temperature in the dark for 1 hour; wash 3 times with TBST at room temperature, 5 minutes each time.

[0063] 7) Development: Develop using an Odyssey dual-color imager.

[0064] 3. Construction of recombinant plasmids:

[0065] 1) Primer design: Primers were designed based on the target sequence found in NCBI. The primer sequences are shown in SEQ ID No. 16-39 below.

[0066]

[0067]

[0068]

[0069] 2) PCR amplification of the target fragment: obtaining the reverse transcription product; obtaining and using existing plasmids. Max DNAPolymerase (R045A, Takara)

[0070] PCR amplification system preparation

[0071]

[0072] PCR amplification reaction procedure

[0073]

[0074] 3) Enzyme digestion:

[0075] Preparation of enzyme digestion system

[0076]

[0077] Enzyme digestion reaction procedure

[0078]

[0079]

[0080] 4) Ligation sequencing: Ligation was performed using the Beyotime Seamless Cloning Kit (D7010M). For specific precautions, please refer to the product manual.

[0081] 4. Construction of Short hairpin RNA (ShRNA) plasmid

[0082] 1. Primer design: Design the target gene sequence according to the following method, and the primers are shown in SEQ ID No. 40-55.

[0083] (1) Review relevant literature on the target gene

[0084] (2) Merck website: https: / / www.sigmaaldrich.cn

[0085] (3) Thermo Fisher Scientific website: https: / / rnaidesigner.thermofisher.com

[0086]

[0087]

[0088] 2. Synthesize Oligos sequences:

[0089] (1) Prepare 20 μL of oligos sequence synthesis system

[0090] Preparation of the Oligos system

[0091]

[0092] (2) Annealing procedure: Place in a 100℃ water bath for 5 minutes and then slowly cool to room temperature.

[0093] 3. Enzyme digestion: Restriction endonucleases AgeⅠ and EcoRI linearized the pLKO.1 vector.

[0094] Preparation of enzyme digestion system

[0095]

[0096] 4. Connection

[0097] For specific precautions regarding the use of Beyotime's ultra-fast T4 DNA ligase (D7009M), please refer to the product instructions.

[0098] 5. Lentiviral packaging and purification:

[0099] 1) Cell preparation: Each batch of revived HEK293T cells should be passaged no more than 20 times. The virus can be packaged starting from the third generation after revival.

[0100] 2) Prepare plasmids:

[0101] a) Two-plasmid system: Total plasmid amount 40 μg (target plasmid 15 μg, pSPA 18 μg, pMD2G 7 μg)

[0102] b) Three-plasmid system: Total plasmid amount 58 μg (target plasmid 15 μg, pRSV.REV 18 μg, pMD2G 18 μg, pMDLg-pRRE 7 μg)

[0103] 3) Prepare for transfection: Use product (Polyethylenimine Linear (PEI) MW40000 (rapid lysis)) or Lipofectamine TM Transfection was performed at 3000.

[0104] 4) Collect supernatant: Collect cell supernatant in 50mL centrifuge tubes at 24h and 48h after medium change.

[0105] 5) Concentrate the supernatant: Centrifuge the cell supernatant at 2000 rpm for 5 minutes and filter using a 0.45 μm filter.

[0106] 6) Centrifuge at 10000g at 4℃ for 18h, with an acceleration of 5 and a deceleration of 0.

[0107] 7) Virus preservation: Remove the virus tube from the centrifuge, carefully aspirate the supernatant, leaving approximately 1.5 mL of supernatant. Mix thoroughly by pipetting, aliquot into 3 tubes, and freeze at -80°C. Label with the virus name, date, and batch number.

[0108] 6. Construction of stable cell lines:

[0109] 1) Determine the optimal antibiotic screening concentration: Before lentiviral infection, first determine the optimal antibiotic screening concentration for killing the target cells.

[0110] 2) Cell plating: For adherent cells, prepare 500 μL of 0.5 × 10⁻⁶ cells one day in advance. 6 The cells to be infected were seeded in a 24-well plate and transfected the next day.

[0111] 3) Prepare the virus: Take the virus out of the -80℃ freezer in advance and place it on ice to wait for it to thaw.

[0112] 4) Viral infection: Take out the cells plated the day before and add the prepared virus drop by drop.

[0113] 5) Supplement the culture medium: After 24h and 48h, replenish the medium in time and divide the wells.

[0114] 6) Cell screening: Cell screening begins 72 hours after the virus is infected, using the optimal antibiotic concentration for killing target cells as determined previously.

[0115] 7) Cell validation: One week after drug screening, if fluorescence is observed, collect total RNA or protein from cells to detect the viral infection effect by observing that the fluorescence rate reaches 80-90%, and prepare for cell cryopreservation.

[0116] 7. Immunofluorescence of adherent cells:

[0117] 1) Cell treatment: First count the cells to determine the number of cell smears. Then, gently mix and fix the cells with 1 mL of 4% paraformaldehyde for 20 min. Wash once with PBS. Add 1 mL / well of Blocking Buffer to immerse the smears and block for 30 min.

[0118] 2) Primary antibody incubation: Dilute the primary antibody to Blocking Buffer according to the antibody instructions and incubate at room temperature for 3 hours.

[0119] 3) Secondary antibody incubation: (room temperature, protected from light) The procedure is the same as that for primary antibody incubation. Incubate at room temperature for 1 hour.

[0120] 4) DAPI staining (room temperature, protected from light): Dilute DAPI 1:1000 in PBS and incubate in the dark for 3 min.

[0121] 5) Mounting: Use mounting medium and nail polish to mount the film.

[0122] 6) Take pictures using a Confocal SP8 microscope.

[0123] 8. Immunoprecipitation:

[0124] 1) Preparation of common cell proteins: Similar to the Western blot portion of protein immunoblotting, it requires at least 30 million cells.

[0125] 2) Protein A / G pretreatment: 30 μL each of Protein A and G, washed with TBS, centrifuged at 1000 g for 30 s at 4 °C, and repeated 3 times.

[0126] 3) Whole cell lysis buffer preparation: Add an appropriate volume of RIPA lysis buffer containing protease inhibitors according to the cell quantity, place on ice at 4°C for lysis for 30 min, and shake to mix every 5 min.

[0127] 4) Protein supernatant after cell lysis:

[0128] a) IP group: Add an appropriate amount of negative control (Control IgG) and an appropriate amount of washed Protein A / G premixed agarose beads, incubate at 4°C with full rotation for 30 min-1 h to eliminate nonspecific background.

[0129] b) Input group: Take 2.5%-5% whole cell lysate as the input group, add 6X protein loading, boil at 100℃ for 10 min, and store at -20℃ for later use.

[0130] 5) Antibody incubation:

[0131] a) After IgG incubation, centrifuge at 1000g for 30 seconds at 4°C, then allow to stand at room temperature for 10 minutes to allow the IgG antibody and its bound proteins to precipitate slowly. Both the supernatant and the precipitate are retained after centrifugation; the precipitate serves as the IgG negative control group.

[0132] b) Supernatant: Transfer the supernatant to a new EP tube, add an appropriate volume of primary antibody according to the antibody instructions, and incubate at 4°C with slow rotation overnight (8-12h) to facilitate the full binding of the antibody and the target protein.

[0133] c) Precipitation (IgG negative control group): Add 1 mL TBS to resuspend, centrifuge at 1000g for 30 s at 4℃, repeat three times; add 20 μL TBS to resuspend, then add 6X protein loading to cook the protein, cook for 10 min, and store at -20℃.

[0134] 6) Sample protein denaturation:

[0135] a) The next day, add 30 μL of Protein A / G premixed agarose beads to the supernatant and continue to incubate at 4°C with slow rotation for 3 hours to allow the supernatant to fully combine with the beads.

[0136] b) After 3 hours, centrifuge at 1000g for 30 seconds at 4°C and discard the supernatant. Wash the precipitate three times with pre-cooled 1mL TBS, centrifuging at 1000g for 30 seconds each time at 4°C. Resuspend in 20μL TBS, add 4μL 6X protein loading solution to cook the protein, and store as the IP group at -20°C.

[0137] 7) Western blot analysis of proteins: Input group, IgG group, and IP group were detected together.

[0138] 9. Denaturing immunoprecipitation:

[0139] 1) Preparation of common cell proteins: Same as the previous immunoprecipitation procedure.

[0140] 2) Protein A / G pretreatment: Same as the previous immunoprecipitation procedure.

[0141] 3) Obtaining whole-cell lysate:

[0142] a) For each sample, add 200 μL of protein lysis buffer RIPA (containing the required protease inhibitors PMSF, NEM, aprotitin, leupeptin, and pepstin) and a mixed solution containing 2% SDS, and shake the cell sample to mix.

[0143] b) Place the shaken and mixed sample in a 100°C water bath for 10 minutes to allow the protein to denature.

[0144] c) After 10 minutes, remove the sample and wait for it to cool to room temperature. Do not place it directly on ice.

[0145] d) After the sample has returned to room temperature, add 1.8 mL of RIPA lysis buffer containing protease inhibitors (containing the required protease inhibitors PMSF, NEM, aprotitin, leupeptin and pepstin), place on ice at 4°C for lysis for 30 min, and shake to mix every 5 min.

[0146] 4) The remaining procedures are the same as those for immunoprecipitation.

[0147] Example 2: Identification of SUMO2 / 3 modified specific sites and SIM domains in LAMP2A

[0148] This embodiment, through a series of online SUMO modification site and interaction SIM motif prediction websites (SUMOplot, SUMOsp, JASSA, and GPS-SUMO2), comprehensively evaluated and identified 7 potential SUMO modification sites and 2 SIM motifs in LAMP2A. Corresponding LAMP2A modification site mutants were constructed, and LAMP2A mutants tagged with FLAG were co-expressed with HA-tagged SUMO2 or SUMO3 in human embryonic kidney KEK293T cells. Denaturing immunoprecipitation confirmed that the SUMO2-specific high-level binding sites were amino acids 104 and 289 of LAMP2A, and the SUMO3-specific high-level binding sites were amino acids 132 and 391-393 of LAMP2A. Subsequently, double mutants of LAMP2A modification were constructed based on the major SUMO2 and SUMO3 modification sites. Overexpression and poly(dA:dT) treatment were performed using the same methods as described above to detect and analyze changes in LAMP2A modification levels. The results are as follows: Figure 2 As shown, when the K104 and K289 sites of LAMP2A are mutated simultaneously, the SUMO2 modification level is significantly reduced, while the SUMO3 modification level remains unchanged. Conversely, when the K132 and SIM1 sites of LAMP2A are mutated simultaneously, the SUMO3 modification level is significantly reduced, while the SUMO2 modification level remains unchanged.

[0149] In summary, LAMP2A mainly undergoes SUMO2 modification at K104 and K289 sites, while SIM1 is more likely to undergo SUMO3 modification at K132 site.

[0150] Example 3: Functional detection of SUMO2 / 3 specific site modification in LAMP2A

[0151] 1. TRIM32 regulates LAMP2A SUMO modification, inhibiting KSHV viral copy number and expression of key viral proteins.

[0152] To further verify whether TRIM32 regulates CMA through mediating SUMO modification of LAMP2A and exerts the aforementioned function, in this embodiment, LAMP2A and its modified mutants, as well as TRIM32 co-expression, were reversibly transfected in the iSLK-Bac16-shLAMP2A stable cell line. 24 hours after transfection, KSHV was activated by Dox induction, and the expression of RTA and MEF2D was detected by Western blotting. Figure 3 A), and the viral load in cell supernatant was detected by fluorescence quantitative PCR. Figure 3 B) The results showed that during the KSHV latency period, TRIM32 promoted CMA activation by mediating SUMO modification of LAMP2A at sites K104, K289, and K132, respectively, although the degree of effect of different types of modifications at different sites varied. During the KSHV lysis and replication phase, TRIM32 also activated CMA by mediating SUMO modification of LAMP2A. In summary, under KSHV latent infection, TRIM32 activates CMA by mediating SUMO modification of LAMP2A, thereby promoting RTA degradation and inhibiting viral particle release, thus maintaining KSHV latent infection.

[0153] 2. Effects of TRIM32-regulated LAMP2A SUMO modification on KSHV-related tumors

[0154] To further verify whether TRIM32 exerts its tumorigenic effect by mediating SUMO modification of LAMP2A, this embodiment co-expressed TRIM32 with different LAMP2A SUMO modification site mutants in KMM-shLAMP2A stable cell lines, and set up an empty vector control. A mouse subcutaneous tumorigenesis model was then conducted. The results are as follows: Figure 4As shown in AC, compared with overexpression of wild-type LAMP2A, overexpression of LAMP2A-K289,104R significantly reduced tumor volume and weight in mice, and also significantly reduced angiogenesis. When TRIM32 was co-expressed, no significant changes were observed in tumor volume, weight, or angiogenesis. Similarly, overexpression of LAMP2A-K132R-SIM1 also significantly reduced tumor volume and weight, and significantly reduced angiogenesis. When TRIM32 was co-expressed, no significant changes were observed in tumor volume, weight, or angiogenesis. This suggests that during KSHV infection, TRIM32 can mediate SUMO modification of LAMP2A at K104, K132, and K289 sites, thereby regulating LAMP2A-induced CMA activation, promoting RTA degradation and tumorigenesis. Furthermore, different SUMO modification sites show varying degrees of effect in promoting KSHV-related tumor development and progression.

[0155] The experimental steps involved in this embodiment are as follows:

[0156] 1. Quantitative determination of viral copy number:

[0157] 1) Culture and process cells according to experimental requirements.

[0158] 2) Concentrate virus particles in cell supernatant: Use a universal virus concentration kit (C2901M, Beyotime).

[0159] 3) Remove the cells that have been cultured and processed in the incubator and collect the cell supernatant.

[0160] 4) Concentrate the collected cell supernatant according to the virus concentration kit. For detailed operating instructions, please refer to the general virus concentration kit (C2901M, Beyotime).

[0161] 5) Extracting viral supernatant particles: using The Viral DNA / RNA Kit (ER201-01, TransgeneBiotech) was used to extract the obtained viral concentrate.

[0162] 6) Quantification of viral copy number: Quantification was performed using our laboratory's rapid detection and quantification reagents and kits for various human herpesvirus subtypes (patent number 20171011884609) and conventional Q-PCR methods. The Q-PCR primers are shown in Table 1 below:

[0163] Table 1

[0164]

[0165] 3. BALB / c nude mouse tumor model:

[0166] 1) Prepare mice: Purchase 4-6 week old female BALB / c-nu athymic nude mice, acclimatize them in an SPF-grade mouse house for 7 days, and weigh and record the mice one day before inoculation.

[0167] 2) Cell preparation: Culture cells to 1.5 times the required inoculation volume and collect them in centrifuge tubes on the day of inoculation; mix Matrigel with blood-free and antibiotic-free culture medium at a ratio of 1:1 as needed for inoculation; dispense the cell mixture into EP tubes and place them on ice for inoculation.

[0168] 3) Mouse inoculation: Subcutaneous injection was used.

[0169] 4) Tumor observation: Tumor growth was monitored and mouse weight was measured every 2 days after injection.

[0170] 5) Dissecting mice: About 20 days after tumor formation, mice were dissected to detect and record the size and weight of tumors in each group.

[0171] Example 4: Synthesis of short peptides at LAMP2A SUMO-modified sites

[0172] In this embodiment, based on the short peptides screened in Example 2 that are modified by SUMO with lysosomal membrane protein 2A and related to K104, K289K, K132, and SIM1 sites, corresponding short peptide derivatives for treating KSHV-related tumors, namely L2AK104, L2AK289, L2AK132, and L2ASIM1, were designed. The short peptide derivatives consist of the aforementioned short peptides and a leading transmembrane peptide; the amino acid sequences of the short peptides at K104, K289, K132, and SIM1 sites are SEQ ID No. 1: WIANFTKAASTYS, SEQ ID No. 2: DFVFAVKNEN RFY, SEQ ID No. 3: FPDADEDKGILTVD, and SEQ ID No. 4: LAGVL ILVLLAY, respectively. The leading transmembrane peptide is attached to the N-terminus of the aforementioned short peptides, and the amino acid sequence of the transmembrane peptide is as shown in SEQ ID No. 5: YGRKKRRQRRR. The short peptides at sites K104, K289, K132, and SIM1 correspond to the short peptide derivatives L2AK104, L2AK289, L2AK132, and L2ASIM1, respectively. Therefore, the amino acid sequences of the short peptide derivatives L2AK104, L2AK289, L2AK132, and L2ASIM1 are as follows: SEQ

[0173] ID No.6: YGRKKRRQRRRWIANFTKAASTYS, SEQ ID No.7: YGRKKRRQRRRDFVFAVKNENRFY, SEQ ID No.8: YGRKKRRQRRRFPDAEDKGI LTVD, SEQ ID No.9: YGRKKRRQRRRLAGVLILVLLAY.

[0174] To further verify the importance of the binding site of the SUMO molecule in the peptide sequence, this embodiment designed corresponding short peptide derivatives with mutated binding sites: L2AK104R, L2AK289R, L2AK132R, and L2AmSIM1. Their amino acid sequences are as follows: SEQ ID No. 10: YGRKKRRQRRRWIANFTRAASTYS, SEQ ID No. 11: YGRKKRRQRRRD FVFAVRNENRFY, SEQ ID No. 12: YGRKKRRQRRRFPDAEDRGILTVD, and SEQ ID No. 13: YGRKKRRQRRRLAGAAAAAALAY. All the above peptide sequences (short peptide derivatives and short peptide derivatives with mutated binding sites) were prepared by solid-phase synthesis, and the purity of the peptides was detected by HPLC. Figure 5 As shown in AH and Table 2A-H, the chromatograms show that the purity of all four polypeptides is greater than 95%.

[0175] Table 2A. HPLC detection parameters for L2AK104

[0176]

[0177] Table 2B. HPLC detection parameters for L2AK104R

[0178]

[0179] Table 2. HPLC detection parameters for C.L2AK289

[0180]

[0181] Table 2. HPLC Detection Parameters for D.L2AK289R

[0182]

[0183] Table 2. HPLC Detection Parameters for E.L2AK132

[0184]

[0185] Table 2. HPLC detection parameters for F.L2AK132R

[0186]

[0187]

[0188] Table 2. HPLC detection parameters for G.L2ASIM1

[0189]

[0190] Table 2. HPLC detection parameters for H.L2AmSIM1

[0191]

[0192] Example 5: Effects of LAMP2A-related SUMO-modified peptides on cell viability and toxicity

[0193] Cell viability was assessed using the CCK-8 assay to observe the effects of peptides L2AK104, L2AK289, L2AK132, and L2ASIM1 on the activity of KSHV-positive cells. The KSHV-positive cell line iSLK-Bac16 was seeded into 96-well plates at 20,000 cells per well, with 5 μM, 10 μM, 20 μM, and 30 μM peptides added simultaneously. An untreated group and a control group were established. Cells were incubated for 24 h, followed by the addition of 10 μL of CCK-8 solution at room temperature in the dark for 2 h. Cell viability was then calculated using a microplate reader at 450 nm. Figure 6 As shown, the results indicate that these peptides have no significant killing effect on KSHV-positive cell lines, suggesting that they have low cytotoxicity.

[0194] The experimental steps involved in this embodiment are as follows:

[0195] 1. Cell proliferation-toxicity assay: CCK-8 assay kit (Lablead, CK001)

[0196] 1) Prepare 100 μl of cell suspension in a 96-well plate and culture it for 24 hours (at 37°C and 5% CO2) as required for the experiment.

[0197] 2) Stimulate the culture plate with different concentrations of the test drug.

[0198] 3) Incubate the culture plate in an incubator for an appropriate period of time.

[0199] 4) Add 10 μl of CCK-8 solution to each well.

[0200] 5) Continue incubation in the cell culture incubator for 1-4 hours, depending on the cell type and cell density and other experimental conditions.

[0201] 6) Measure the absorbance at 450 nm using an enzyme-linked immunosorbent assay (ELISA) reader.

[0202] 7) If the analyte has oxidizing or reducing properties, replace the culture medium with fresh medium before adding CCK8 (remove the culture medium, wash the cells twice with the culture medium, and then add fresh culture medium) to eliminate the drug's influence. Of course, if the drug's influence is relatively small, you can skip replacing the culture medium and directly subtract the blank absorbance after adding the drug to the culture medium.

[0203] 8) Calculation of CCK-8 cell viability:

[0204] Cell viability (%) = [(AS-Ab) / (AC-Ab)] × 100%

[0205] AS: Experimental wells (containing cell culture medium, CCK-8, and toxic substances)

[0206] AC: Control wells (containing cell culture medium, CCK-8, and no toxic substances)

[0207] Ab: Blank wells (free from cell culture medium, toxic substances, and CCK-8)

[0208] Example 6: LAMP2A SUMO-modified short peptide inhibits KSHV-related tumor growth.

[0209] Given that synthetic short peptides may competitively inhibit LAMP2A function through SUMO modification, it is possible to investigate whether synthetic short peptides can inhibit LAMP2A function, thereby suppressing the growth and proliferation of KSHV-related tumors. To further verify this hypothesis, this study transfected KSHV-positive cells (KMM and iSLK-Bac16) with FLAG-tagged LAMP2A and various peptides, and established PBS-treated and control peptide-treated groups to conduct subcutaneous tumorigenesis model experiments in mice. The results are as follows: Figure 7As shown in the AD diagram, compared with the PBS and Control groups, mice in the L2AK289, L2AK289+L2AK104, L2ASIM1, and L2AK132+L2ASIM1 groups showed significantly reduced tumor volume and weight, and significantly decreased angiogenesis. However, no significant changes were observed in tumor volume, weight, or angiogenesis in the corresponding L2AK289R, L2AK289R+L2AK104R, and L2AmSIM1 groups. The L2AK132R+L2AmSIM1 group also showed a significant reduction in tumor volume and weight. This indicates that peptides L2AK289 and L2ASIM1 competitively inhibit SUMO modification of LAMP2A at its modification sites, thereby reducing LAMP2A expression levels and regulating the growth, proliferation, and angiogenesis of KSHV-related tumors.

[0210] The specification and drawings of this invention are intended to be illustrative rather than restrictive. Based on this invention, those skilled in the art can make substitutions and modifications to some of the technical features without creative effort, and all such modifications are within the scope of protection of this invention.

Claims

1. A short peptide derivative based on lysosomal membrane protein 2A, characterized in that, The short peptide derivative is L2AK289 or L2ASIM1; the amino acid sequences of L2AK289 or L2ASIM1 are shown in SEQ ID No. 7 and SEQ ID No. 9, respectively.

2. A pharmaceutical preparation, characterized in that, The pharmaceutical preparation includes one or two of the short peptide derivatives as described in claim 1.

3. The use of the short peptide derivative as described in claim 1 in the preparation of antiviral infection drugs, characterized in that, The virus is Kaposi's sarcoma virus (KSHV), and the short peptide derivative can inhibit the increase in the viral copy number of KSHV.

4. The use of the short peptide derivative as described in claim 1 in the preparation of a medicament for treating tumors, characterized in that, The tumor is caused by Kaposi's sarcoma virus (KSHV), and the short peptide derivative inhibits the proliferation of KSHV-infected tumor cells, thereby inhibiting tumor growth and angiogenesis.

Citation Information

Patent Citations

  • Vaccine medicine target SIM resisting Kaposi's sarcoma-associated herpesvirus

    CN104447964A

  • Gamma secretase inhibitor for treatment of herpesvirus infection

    US20090060881A1